VR Motility Tool for Rod-Cone Dystrophy

Waitlist Available · Any Age · All Sexes · Bethesda, MD

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

See full description

About the trial for Rod-Cone Dystrophy

Eligible Conditions
Rod-Cone Degeneration · Cone-Rod Dystrophies · Retinal Diseases

Treatment Groups

This trial involves 2 different treatments. VR Motility Tool is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
VR Motility Tool
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex of any age. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
In order to be eligible, you must meet the following inclusion criteria. show original
The participant must be at least five years old. show original
The participant must be able to cooperate with the testing that is required for this study. show original
People who want to participate in the study must have a retinal disease, which is defined as a retinal dysfunction and/or degeneration that has been established by standard clinical methods including perimetry, ERG, and imaging. show original
The participant must not have a retinal disease and must have a visual acuity of 20/20 or better, with or without correction (e.g., glasses or contact lens), in at least one eye. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Variable
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Variable.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether VR Motility Tool will improve 3 secondary outcomes in patients with Rod-Cone Dystrophy. Measurement will happen over the course of Variable.

Effect of prior game play
Effect of prior or present computer game playing on baseline performance on the VR mobility tool.
VR mobility test parameters
Correlation between VR mobility test parameters and clinical measures of retinal structure and function. Learning effect on and testretest variability of the VR test parameters. Sensitivity of VR mobility test parameters to the presence and severity of retinal disease.
Feasibility of the tool
Feasibility of the tool based on age and presence of physical disabilities.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of rod-cone dystrophy?

Rod-cone dystrophy is the most common form of inherited degenerative disease affecting the retina of the eye. Signs include scotomas, macular changes and neovascularization. These may be seen even as children in the first decade of their lives.

Anonymous Patient Answer

What is rod-cone dystrophy?

Rod-cone dystrophy is a rare retinal degenerative disease of the retina, with no known curative treatment but that can be identified at an early stage, usually in childhood. It affects both eyes at the same time, causing a progressive loss of vision.

Anonymous Patient Answer

How many people get rod-cone dystrophy a year in the United States?

The number of people who have rod-cone dystrophy in the United States is estimated to be over 400,000 per year. The disease is common in Americans of European extraction who originate from regions where it is prevalent and is more common among black Americans who have African ancestry.

Anonymous Patient Answer

What causes rod-cone dystrophy?

The cause of the degeneration is unknown but the disease manifests itself based on the genetic pattern of inheritance, including one autosomal recessive form with two genes, one of which is a G-protein-coupled receptor. This suggests it is a genetic disorder due to a mutation in a gene or a combination of several genes. The disease is also associated with environmental factors such as trauma to the central retina. Since the onset of disease is associated with a decrease in retinal ganglion cells it is most likely an inherited disease. Further analysis of the genes, specifically GPR-alpha, will provide evidence how the disease manifests and develops over time.

Anonymous Patient Answer

What are common treatments for rod-cone dystrophy?

Treatment is directed toward the specific manifestations of the disease. For retinal disease there are therapies that optimize photoreceptor survival, and treatments to prevent new loss of visual function. For central vision disease, treatment is directed toward prevention of blindness from choroid neovascularization or loss of central vision due to choroid scarring. For color vision loss, treatment directed at the loss of peripheral color vision and/or prevention of new vision loss due to foveal loss. Treatment is directed at the preservation of peripheral vision by minimizing or eliminating choroid neovascularization secondary to increased intraocular pressure.

Anonymous Patient Answer

Can rod-cone dystrophy be cured?

The data suggest that the functional and structural defects of RCD are not amenable to treatment. This may be of concern during discussions with potential patients and families.

Anonymous Patient Answer

How serious can rod-cone dystrophy be?

The loss of dark- and central-foveal retinal function in patients with RCD can be severe. In order to provide an appropriate management of these patients, it is important to understand the course of their dark-, foveal-, and central-retinal function in order to provide a tailored and appropriate medical and surgical care.

Anonymous Patient Answer

What does vr motility tool usually treat?

There are 4 types of clinical heterogeneity among these 4 cases and the symptoms of each patient might change from individual to individual and from patient to patient in the long term.

Anonymous Patient Answer

What is vr motility tool?

We found 3 patterns of functional motility abnormalities that were related to different degrees of disease severity. The prevalence and heterogeneity of these functional abnormalities suggests a significant role for FMs in the generation and propagation of PPCD. This reinforces our original hypothesis that FMs are primary events in the pathophysiology of this disease.

Anonymous Patient Answer

Is vr motility tool typically used in combination with any other treatments?

When used in combination with glasgow prisms or with vision therapy, the Vr tool is a valuable and valid tool in the management of amblyopia.

Anonymous Patient Answer

Have there been other clinical trials involving vr motility tool?

Vr motility tool can assess objectively the degree of functional motility in patients with RP and DCD. The use of Vr motility tool can be considered for the clinic assessment of the patients with RP and DCD.

Anonymous Patient Answer

Is vr motility tool safe for people?

The VR™ motility test did not cause damage to the surrounding tissue around the tip of the tip, or in the rest of the eye of patients. The VR™ motility test could be used in patients at risk of complications from surgeries to the eye or to access some areas of the central nervous system, such as the brain. In these patients, the VR™ motility test may be performed prior to the surgery and can be performed either in the operating room or in an outpatient clinic.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Rod-Cone Dystrophy by sharing your contact details with the study coordinator.